price month
expand genom offer nugen
outperform result slightli expect
revis sales/adj ep respect
reflect concurr announc acquisit nugen get tecan
attract market next-gener sequenc reagent
trigger us slightli upgrad medium term growth margin forecast
also roll dcf lift target price
retain outperform rate think manag gener major
valu put compani substanti net cash posit work
expand genom offer acquisit nugen tecan
get next-gener kit sampl prepar reagent nice
complement tecan workstat develop get
market come year manag target
increment non acquir sale initi translat
meaning increment sale growth
acquisit make strateg sens us note nugen come
particular cheap light nugen oper loss posit
slightli less ev/sal paid tecan result
underli sale growth fx adj ebit margin
increas plu strong demand new gx solut put tecan well
track meet full year guidanc view increment
beyond nugen fire power least estim
given fragment consolid natur life scienc
industri optimist manag also find larger target
catalyst risk ceo david martyr cs roadshow new york
septemb present cs mid cap confer zurich
novemb result march
valuat valu tecan per share dcf model
year sale growth old adj ebit margin old
tradit multipl tecan trade forward price-to-earnings
ev/sal line industri peer averag
valuat metric
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
tecan group ag switzerland-bas compani engag
develop product distribut advanc autom
detect solut life scienc laboratori
price aug rate outperform target price analyst christoph gretler
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
ramp oem partner project exce expect
averag underli growth midterm touch
price target reach per share
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
pick dako omni sale orthovis begin
declin mid term price target could reach
price rel chart measur perform swiss market
ind close
spot exchang rate
figur varianc cs estim consensu
consensu varianc consensu
sale growth local currenc growth driven doubl digit sale increas partner busi
moder growth local currenc order entri order backlog grow double-digit rate
sale growth local currenc continu strong growth exist instrument platform
driven sale growth well effici gain
figur cs estim chang
sfr million unless otherwis state
sale
ebit
sfr million unless otherwis state
 tax adj ebit
 chang work capit wc
 chang asset
 invest intang
equiti valu per share sfr
oper work capit sale
capital-expenditure sale
weight averag cost capit wacc
sfr million unless otherwis state
growth local currenc
sale busi line
gross profit product line cs estim
oper profit product line
sfr million unless otherwis state
good sold
net sale
net sale
net sale
gross fix asset
gross invest fix asset
depreci
net sale
amortis intang
gross invest intang
currenc gain loss
compani mention price
